Ondine Biomedical Inc.
OBIMF
$0.14
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 366.10K | 352.90K | 425.10K | 436.20K | 313.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 366.10K | 352.90K | 425.10K | 436.20K | 313.90K |
| Cost of Revenue | 128.70K | 124.00K | 142.20K | 145.90K | 120.60K |
| Gross Profit | 237.40K | 228.90K | 282.90K | 290.30K | 193.30K |
| SG&A Expenses | 1.78M | 1.72M | 2.22M | 2.28M | 1.75M |
| Depreciation & Amortization | 101.90K | 98.20K | 93.90K | 96.40K | 99.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.89M | 4.71M | 4.57M | 4.69M | 3.18M |
| Operating Income | -4.52M | -4.36M | -4.15M | -4.26M | -2.86M |
| Income Before Tax | -4.54M | -4.38M | -4.05M | -4.16M | -2.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.54M | -4.38M | -4.05M | -4.16M | -2.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.54M | -4.38M | -4.05M | -4.16M | -2.84M |
| EBIT | -4.52M | -4.36M | -4.15M | -4.26M | -2.86M |
| EBITDA | -4.41M | -4.25M | -4.11M | -4.22M | -2.83M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 437.24M | 437.24M | 307.73M | 307.73M | 241.47M |
| Average Diluted Shares Outstanding | 437.24M | 437.24M | 307.73M | 307.73M | 241.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |